Trial reportPLoS neglected tropical diseases2010
Cost-effectiveness of a chemoprophylactic intervention with single dose rifampicin in contacts of new leprosy patients.
Trial report in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Measuring endemicity and burden of leprosy across countries and regions: A systematic review and Delphi survey.PLoS neglected tropical diseases · 2021Pooled it
- Revised estimates of leprosy disability weights for assessing the global burden of disease: A systematic review and individual patient data meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Acceptability and feasibility of chemoprophylaxis with single-dose rifampicin in four leprosy-endemic districts in Benin.PLoS neglected tropical diseases · 2025Article
- A Review of the Efficacy, Safety, and Feasibility of Rifamycin-Based Post-Exposure Chemoprophylaxis for Leprosy.Tropical medicine and infectious disease · 2025Review
- Leprosy.Nature reviews. Disease primers · 2024Review
- Economic evaluation of a leprosy innovation project in Northern Nigeria: cost-effectiveness analysis.Cost effectiveness and resource allocation : C/E · 2022Article
- Implementation approaches for leprosy prevention with single-dose rifampicin: A support tool for decision making.PLoS neglected tropical diseases · 2022Review
- Article
- Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis.PLoS neglected tropical diseases · 2020Article
- The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis.Research and reports in tropical medicine · 2020Review
- Leprosy services in primary health care in India: comparative economic cost analysis of two public-health settings.Tropical medicine & international health : TM & IH · 2019Article
- Trend analysis of leprosy in Morocco between 2000 and 2017: Evidence on the single dose rifampicin chemoprophylaxis.PLoS neglected tropical diseases · 2018Article
- Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention.PLoS neglected tropical diseases · 2018Article
- Household expenditure on leprosy outpatient services in the Indian health system: A comparative study.PLoS neglected tropical diseases · 2018Article
- Leprosy in a texan.Proceedings (Baylor University. Medical Center) · 2015Article
- Cost-effectiveness analysis of three leprosy case detection methods in Northern Nigeria.PLoS neglected tropical diseases · 2012Article
- Current Situation of Leprosy in India and its Future Implications.Indian dermatology online journalReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith 249,007 new leprosy patients detected globally in 2008, it remains necessary to develop new and effective interventions to interrupt the transmission of M. leprae. We assessed the economic benefits of single dose rifampicin (SDR) for contacts as chemoprophylactic intervention in the control of leprosy.
methodsWe conducted a single centre, double blind, cluster randomised, placebo controlled trial in northwest Bangladesh between 2002 and 2007, including 21,711 close contacts of 1,037 patients with newly diagnosed leprosy. We gave a single dose of rifampicin or placebo to close contacts, with follow-up for four years. The main outcome measure was the development of clinical leprosy. We assessed the cost effectiveness by calculating the incremental cost effectiveness ratio (ICER) between the standard multidrug therapy (MDT) program with the additional chemoprophylaxis intervention versus the standard MDT program only. The ICER was expressed in US dollars per prevented leprosy case.
findingsChemoprophylaxis with SDR for preventing leprosy among contacts of leprosy patients is cost-effective at all contact levels and thereby a cost-effective prevention strategy. In total, $6,009 incremental cost was invested and 38 incremental leprosy cases were prevented, resulting in an ICER of $158 per one additional prevented leprosy case. It was the most cost-effective in neighbours of neighbours and social contacts (ICER $214), slightly less cost-effective in next door neighbours (ICER $497) and least cost-effective among household contacts (ICER $856).
conclusionChemoprophylaxis with single dose rifampicin given to contacts of newly diagnosed leprosy patients is a cost-effective intervention strategy. Implementation studies are necessary to establish whether this intervention is acceptable and feasible in other leprosy endemic areas of the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.